Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | ECE1 | P42892 | 4/20 | 0.37 |
| ▸ | MME | P08473 | 5/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397511 | 1.00 | KDM4E (0.43) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL18921925 | 0.91 | ACE (0.35) | ACEECE1MMEGNPAT | |
| SCHEMBL25355936 | 0.90 | ACE (0.36) | ACEECE1MMEGNPAT | |
| SCHEMBL29461561 | 0.89 | ACE (0.36) | ACEECE1MME | |
| SCHEMBL29461611 | 0.87 | BACE1 (0.39) | ACEECE1MME | |
| SCHEMBL29912552 | 0.86 | ACE (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL29476103 | 0.86 | FNTA (0.40) | ACEECE1MME | |
| SCHEMBL29615112 | 0.86 | FNTA (0.40) | ACEECE1MME | |
| SCHEMBL29511053 | 0.86 | FNTA (0.40) | ACEECE1MME | |
| SCHEMBL29461716 | 0.85 | ACE (0.40) | ACEECE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | UACA, CRYAA, CRYAB | KDM4E 4859/4885MAPT 231/4885THRB 2059/4885 |
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | CHRNA1, CHRNB1, NPY1R | KDM4E 4444/4885MAPT 232/4885THRB 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.